Literature DB >> 24193666

Deep wound infection after transpedicular fixation of traumatised thoraco-lumbar spine. Case report of 5 patients.

J Feczkó1, A Sárváry.   

Abstract

The authors report 5 deep infections after posterior stabilisation of 96 fractured thoraco-lumbar spine. A transpedicular plate fixation device was used, which was constructed by them. They analyse the reasons of infections and the management of developed wound complications. If the irrigation was ineffective, they left the wound open after debridement and filled up the cavity with Gentamicin PMMA chain. With this management the infections were eliminated withouth neurologic deterioration, but due to infection with considerable loss of spine function.

Entities:  

Year:  1996        PMID: 24193666     DOI: 10.1007/BF00568311

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN: 1633-8065


  6 in total

1.  Posterior lumbar interbody fusion and plates.

Authors:  A D Steffee; D J Sitkowski
Journal:  Clin Orthop Relat Res       Date:  1988-02       Impact factor: 4.176

2.  Stabilization of the lower thoracic and lumbar spine with external skeletal fixation.

Authors:  F P Magerl
Journal:  Clin Orthop Relat Res       Date:  1984-10       Impact factor: 4.176

3.  [Gentamicin-PMMA-beads in treating bone and soft tissue infections (author's transl)].

Authors:  K Klemm
Journal:  Zentralbl Chir       Date:  1979       Impact factor: 0.942

4.  Anterolateral decompression for neural involvement in thoracolumbar fractures. A review of 78 cases.

Authors:  E B Riska; P Myllynen; O Böstman
Journal:  J Bone Joint Surg Br       Date:  1987-11

5.  Gentamicin-PMMA beads. Pharmacokinetic and nephrotoxicological study.

Authors:  G H Walenkamp; T B Vree; T J van Rens
Journal:  Clin Orthop Relat Res       Date:  1986-04       Impact factor: 4.176

6.  Complications following Harrington instrumentation for fractures of the thoracolumbar spine.

Authors:  P C McAfee; H H Bohlman
Journal:  J Bone Joint Surg Am       Date:  1985-06       Impact factor: 5.284

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.